The Effect Of Tafamidis Meglumine In Transthyretin Amyloid Polyneuropathy Patients
Status:
Recruiting
Trial end date:
2023-03-09
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, multicenter study designed to determine the effect of
tafamidis meglumine on TTR stabilization as well as tafamidis meglumine safety, tolerability
and efficacy in ATTR-PN patients in China.
Approximately 10-15 participants are planned to be enrolled. All enrolled participants will
receive oral tafamidis meglumine 20 mg soft capsules once daily for 48 weeks.